Multiple Assemblies exist for SMTL entry 5tq3
Design and Synthesis of a pan-JAK kinase inhibitor clinical candidate (PF-06263276) suitable for the treatment of inflammatory diseases of the lungs and skin; X-RAY DIFFRACTION 2.69 Å

	SMTL ID 5tq3.1 Ligands 4-[3-(1H-benzimidazol-2-yl)-1H-indazol-6-yl]-3-ethylphenol Polypeptides Tyrosine-protein kinase JAK2 Oligo-state monomer
	SMTL ID 5tq3.2 Ligands 4-[3-(1H-benzimidazol-2-yl)-1H-indazol-6-yl]-3-ethylphenol Polypeptides Tyrosine-protein kinase JAK2 Oligo-state monomer